ArticleAntimicrobial agents and chemotherapy2006
Mefloquine induces dose-related neurological effects in a rat model.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 68 citations in OpenAlex.
- Ligand-Based Virtual Screening, Molecular Docking, and Molecular Dynamic Simulations of New β-Estrogen Receptor Activators with Potential for Pharmacological Obesity Treatment.Molecules (Basel, Switzerland) · 2023Article
- Differential Stabilities of Mefloquine-Bound Human andACS omega · 2021Article
- Pentamidine sensitizes FDA-approved non-antibiotics for the inhibition of multidrug-resistant Gram-negative pathogens.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: a review.Malaria journal · 2020Review
- Approval of Tafenoquine for Malaria Chemoprophylaxis.The American journal of tropical medicine and hygiene · 2019Article
- Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines.Malaria journal · 2018Review
- Accidental hydroxychloroquine overdose resulting in neurotoxic vestibulopathy.BMJ case reports · 2017Article
- Mefloquine-associated dizziness, diplopia, and central serous chorioretinopathy: a case report.Journal of medical case reports · 2016Article
- Mefloquine in the nucleus accumbens promotes social avoidance and anxiety-like behavior in mice.Neuropharmacology · 2016Article
- Gap Junction Blockers: An Overview of their Effects on Induced Seizures in Animal Models.Current neuropharmacology · 2016Review
- A small-fish model for behavioral-toxicological screening of new antimalarial drugs: a comparison between erythro- and threo-mefloquine.BMC research notes · 2015Article
- Anticonvulsant effects of mefloquine on generalized tonic-clonic seizures induced by two acute models in rats.BMC neuroscience · 2015Article
- Malaria Prevention, Mefloquine Neurotoxicity, Neuropsychiatric Illness, and Risk-Benefit Analysis in the Australian Defence Force.Journal of parasitology research · 2015Review
- Behavioral effects of mefloquine in tail suspension and light/dark tests.SpringerPlus · 2015Article
- Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine.International journal for parasitology. Drugs and drug resistance · 2014Article
- Recent highlights in anti-protozoan drug development and resistance research.International journal for parasitology. Drugs and drug resistance · 2012Article
- Mefloquine neurotoxicity is mediated by non-receptor tyrosine kinase.Neurotoxicology · 2011Article
- Mefloquine damage vestibular hair cells in organotypic cultures.Neurotoxicity research · 2011Article
- Central nervous system exposure of next generation quinoline methanols is reduced relative to mefloquine after intravenous dosing in mice.Malaria journal · 2011Article
- Expanding the Antimalarial Drug Arsenal-Now, But How?Pharmaceuticals (Basel, Switzerland) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mefloquine is one of the drugs approved by the FDA for malaria chemoprophylaxis. Mefloquine is also approved for the treatment of malaria and is widely used for this purpose in combination with artesunate. However, the clinical utility of the compound has been compromised by reports of adverse neurological effects in some patients. In the present study, the potential neurological effects of mefloquine were investigated with six 7-week-old female rats given a single oral dose of the compound. Potential mefloquine-induced neurological effects were monitored using a standard functional observational battery, automated open field tests, automated spontaneous activity monitoring, a beam traverse task, and histopathology. Plasma mefloquine concentrations were determined 72 h after dosing by using liquid chromatography-mass spectrometry. Mefloquine induced dose-related changes in endpoints associated with spontaneous activity and impairment of motor function and caused degeneration of specific brain stem nuclei (nucleus gracilis). Increased spontaneous motor activity was observed only during the rats' normal sleeping phase, suggesting a correlate to mefloquine-induced sleep disorders. The threshold dose for many of these effects was 187 mg/kg of body weight. This dose yielded plasma mefloquine concentrations after 72 h that are similar to those observed in humans after the treatment dose. Collectively, these data suggest that there may be a biological basis for some of the clinical neurological effects associated with mefloquine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.